BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 18337408)

  • 21. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
    Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
    J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of mitochondrial protein import by mutant huntingtin.
    Yano H; Baranov SV; Baranova OV; Kim J; Pan Y; Yablonska S; Carlisle DL; Ferrante RJ; Kim AH; Friedlander RM
    Nat Neurosci; 2014 Jun; 17(6):822-31. PubMed ID: 24836077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.
    Reddy PH; Shirendeb UP
    Biochim Biophys Acta; 2012 Feb; 1822(2):101-10. PubMed ID: 22080977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor receptor-associated factor 6 (TRAF6) associates with huntingtin protein and promotes its atypical ubiquitination to enhance aggregate formation.
    Zucchelli S; Marcuzzi F; Codrich M; Agostoni E; Vilotti S; Biagioli M; Pinto M; Carnemolla A; Santoro C; Gustincich S; Persichetti F
    J Biol Chem; 2011 Jul; 286(28):25108-17. PubMed ID: 21454471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clearance of mutant huntingtin.
    Li XJ; Li H; Li S
    Autophagy; 2010 Jul; 6(5):663-4. PubMed ID: 20519964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine D1 receptor-mediated aggregation of N-terminal fragments of mutant huntingtin and cell death in a neuroblastoma cell line.
    Robinson P; Lebel M; Cyr M
    Neuroscience; 2008 May; 153(3):762-72. PubMed ID: 18403126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria?
    Sawa A
    J Mol Med (Berl); 2001 Jul; 79(7):375-81. PubMed ID: 11466559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Native mutant huntingtin in human brain: evidence for prevalence of full-length monomer.
    Sapp E; Valencia A; Li X; Aronin N; Kegel KB; Vonsattel JP; Young AB; Wexler N; DiFiglia M
    J Biol Chem; 2012 Apr; 287(16):13487-99. PubMed ID: 22375012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease.
    Busch A; Engemann S; Lurz R; Okazawa H; Lehrach H; Wanker EE
    J Biol Chem; 2003 Oct; 278(42):41452-61. PubMed ID: 12888569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.
    Tebbenkamp AT; Green C; Xu G; Denovan-Wright EM; Rising AC; Fromholt SE; Brown HH; Swing D; Mandel RJ; Tessarollo L; Borchelt DR
    Hum Mol Genet; 2011 Jul; 20(14):2770-82. PubMed ID: 21515588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
    Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
    Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggregation in Huntington's disease: insights through modelling.
    Cajavec B; Bernard S; Herzel H
    Genome Inform; 2005; 16(1):262-71. PubMed ID: 16362929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.
    Legleiter J; Mitchell E; Lotz GP; Sapp E; Ng C; DiFiglia M; Thompson LM; Muchowski PJ
    J Biol Chem; 2010 May; 285(19):14777-90. PubMed ID: 20220138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.